The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial
Open accessAbstract
BACKGROUND: Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus. METHODS: This open-label, randomised clinical trial was undertaken at 30 UK emergency departments at secondary and tertiary care centres. Participants aged 6 months to under 18 years, with convulsive status epilepticus requiring second-line treatment, were randomly assigned (1:1) using a computer-generated randomisation schedule to receive levetiracetam (40 mg/kg over 5 min) or phenytoin (20 mg/kg over at least 20 min), stratified by centre. The primary outcome was time from randomisation to cessation of convulsive status epilepticus, analysed in the modified intention-to-treat population (excluding those who did not require second-line treatment after randomisation and those who did not provide consent). This trial is registered with ISRCTN, number ISRCTN22567894. FINDINGS: Between July 17, 2015, and April 7, 2018, 1432 patients were assessed for eligibility. After exclusion of ineligible patients, 404 patients were randomly assigned. After exclusion of those who did not require second-line treatment and those who did not consent, 286 randomised participants were treated and had available data: 152 allocated to levetiracetam, and 134 to phenytoin. Convulsive status epilepticus was terminated in 106 (70%) children in the levetiracetam group and in 86 (64%) in the phenytoin group. Median time from randomisation to cessation of convulsive status epilepticus was 35 min (IQR 20 to not assessable) in the levetiracetam group and 45 min (24 to not assessable) in the phenytoin group (hazard ratio 1·20, 95% CI 0·91-1·60; p=0·20). One participant who received levetiracetam followed by phenytoin died as a result of catastrophic cerebral oedema unrelated to either treatment. One participant who received phenytoin had serious adverse reactions related to study treatment (hypotension considered to be immediately life-threatening [a serious adverse reaction] and increased focal seizures and decreased consciousness considered to be medically significant [a suspected unexpected serious adverse reaction]). INTERPRETATION: Although levetiracetam was not significantly superior to phenytoin, the results, together with previously reported safety profiles and comparative ease of administration of levetiracetam, suggest it could be an appropriate alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatric convulsive status epilepticus. FUNDING: National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Chin, R. F., Neville, B. G., Peckham, C., Bedford, H., Wade, A., & Scott, R. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69043-0 · Cited by 594
McIntyre, J., Robertson, S., Norris, E., Appleton, R., Whitehouse, W. P., Phillips, B., Martland, T., Berry, K., Collier, J., Smith, S., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66909-7 · Cited by 445
Self-citationMcTague, A., Martland, T., & Appleton, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001905.pub3 · Cited by 237
Self-citationLevetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study
Misra, U. K., Kalita, J., & Maurya, P. K. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6227-2 · Cited by 137
Craig, S. S. (2005) · Neurocritical Care · doi:10.1385/ncc:3:2:161 · Cited by 130
Mundlamuri, R. C., Sinha, S., Subbakrishna, D. K., Prathyusha, P. V., Nagappa, M., Bindu, P. S., Taly, A. B., Rao, G. S. U., & Satishchandra, P. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.04.013 · Cited by 101
Restricted fluid bolus volume in early septic shock: results of the Fluids in Shock pilot trial
Inwald, D. P., Canter, R. R., Woolfall, K., Mouncey, P., Zenasni, Z., O’Hara, C., Carter, A., Jones, N., Lyttle, M. D., Nadel, S., et al. (2018) · Archives of Disease in Childhood · doi:10.1136/archdischild-2018-314924 · Cited by 101
Self-citationLevetiracetam versus phenytoin in management of status epilepticus
Chakravarthi, S., Goyal, M., Modi, M., Bhalla, A., & Singh, P. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.12.013 · Cited by 91
Fuller, K., Wang, Y. Y., Cook, M. J., Murphy, M. A., & D'Souza, W. J. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03563.x · Cited by 84
Cited by
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905795 · Cited by 551
European Resuscitation Council Guidelines 2021: Paediatric Life Support
Van de Voorde, P., Turner, N. M., Djakow, J., de Lucas, N., Martinez-Mejias, A., Biarent, D., Bingham, R., Brissaud, O., Hoffmann, F., Johannesdottir, G. B., et al. (2021) · Resuscitation · doi:10.1016/j.resuscitation.2021.02.015 · Cited by 448
National UK programme of community health workers for COVID-19 response
Haines, A., de Barros, E. F., Berlin, A., Heymann, D. L., & Harris, M. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30735-2 · Cited by 237
Does long‐term phenytoin have a place in Dravet syndrome?
Zographos, G. A., Russ‐Hall, S. J., & Scheffer, I. E. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51684 · Cited by 17
Metadata
- Authors
- Lyttle, M. D., Rainford, N. E. A., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., Woolfall, K., Roper, L., Noblet, J., Lee, E. D., Potter, S., Tate, P., Iyer, A., Evans, V., Appleton, R. E., Pereira, M., Hardwick, S., Messahel, S., Noblet, J., Lee, E. D., Greenwood-Bibby, R., Buchanan, M., Lewis, L., Hughes, S., Hartshorn, S., Rogers, L., Hopkins, J., Lyttle, M. D., Fernandez, D., Potter, S., Lavigne-Smith, H. R., Moulsdale, P., Smith, A., Bingham, T., Ross, J., Ramsey, N., Hacking, J., Mullen, N., Corrigan, P. P., Prudhoe, S., Faza, H., Robinson, G., Sunley, R. C., Smith, C. J., Unsworth, V., Criddle, J., Laque, M., Sheedy, A. B., Anderson, M., Bell, K., Devine, K., Scott, A., Kumar, R., Armstrong, S., Sutherland, E., Cantle, F., Helyer, S., Riozzi, P., Cotton, H., Downes, A. J., Mollard, H., Roland, D., Hay, F., Gough, C., Finucane, S., Bevan, C., Ramsay, R., Walton, E., Maney, J.-A., Dalzell, E., Millar, M., Howells, R. J., Appelboam, A., Mackle, D., Small, J., Neil, A., Choudhery, V., MacLeod, S., Browning, J., O'Neill, T., Grahamslaw, J., Parikh, A., Skene, I., Thomas, R., Potier de la Morandiere, K., Wilson, J. L., Danziger, D., Burke, D., Ramlakhan, S., Evans, J., Morcombe, J., Gormley, S., Barling, J. M., Cathie, K., Bayreuther, J., Ensom, R., Iqbal, Y., Rounding, S., Mulligan, J., Bell, C., McLellan, S., Leighton, S., Sajjanhar, T., Nyirenda, M., Crome, L., Williamson, N., Alcock, A., Edwards, S., Morgan, J., Powell, C. V., Ramesh, C. A., Kamal-Uddin, S., Linney, M., Vamvakiti, K., Floyd, S., & Hobden, G.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 393
- Issue
- 10186
- Pages
- 2125-2134
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2937512232
- Cited by
- 253
- References
- 19
- FWCI
- 24.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)30724-x
- The paper
- Lyttle, M. D., Rainford, N. E. A., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., Woolfall, K., Roper, L., Noblet, J., Lee, E. D., Potter, S., Tate, P., Iyer, A., Evans, V., Appleton, R. E., Pereira, M., Hardwick, S., Messahel, S., Noblet, J., . . . Hobden, G. (2019). Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)30724-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.